OSR Holdings, Inc. (OSRHW) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Jul 21Jul 24Aug 3Aug 10Aug 13Aug 18Aug 21Sep 2

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.6x

Market Cap

$112050.00

MomentumView details →

1D Return

−16.67%

YTD Return

−50.98%

RSI (14)

40.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.6x

Market Cap

$112050.00

RSI (14)

40.4

MomentumView details →

1D Return

−16.67%

YTD Return

−50.98%

ProfitabilityView details →

Gross Margin

−98.82%

Net Margin

−836.91%

EBITDA Margin

−423.86%

ROE (TTM)

−14.52%

ROA (TTM)

−9.08%

Asset Turnover

0.01x

GrowthView details →

Revenue YoY

+351.82%

EPS YoY

−16.42%

FCF YoY

—

Revenue CAGR 3Y

−17.69%

EPS CAGR 3Y

—

EBITDA YoY

−74.71%

EarningsView details →

EPS (Actual)

−$0.03

EPS Surprise

88.50%

Beats (12Q)

2/12

Next Q EPS Est

−$0.27

Avg Surprise (4Q)

78.73%

Rev Surprise

−59.53%

Capital & dividendView details →

Debt/Equity

0.01x

Current Ratio

0.18x

Quick Ratio

0.14x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.81M

Net Income (TTM)

−15.14M

Op. CF (TTM)

−7.20M

Next earningsDec 2, 2026 →

Latest newsMore news →

OSR Holdings, Inc. changed its corporate name to OSR Health, Inc., effective June 11, 2026.75d ago

OSR Holdings, Inc. agreed to purchase all of Vaximm AG's right, title and interest in the VXM01 intellectual property family and certain related assigned contracts for $30 million.95d ago

Similar companies

Jasper Therapeutics, Inc.JSPRW Humacyte, Inc.HUMAW Altamira Therapeutics Ltd.CYTO Instinct Bio Technical Company Holdings Inc. WarrantsBIOTW Vincerx Pharma, Inc.VINC Cingulate Inc.CINGW Find similar companies →

Latest newsMore news →

OSR Holdings, Inc. changed its corporate name to OSR Health, Inc., effective June 11, 2026.75d ago OSR Holdings, Inc. agreed to purchase all of Vaximm AG's right, title and interest in the VXM01 intellectual property family and certain related assigned contracts for $30 million.95d ago Vaximm AG granted BCM Europe AG an exclusive, worldwide license to develop, manufacture and commercialize products based on VXM01.95d ago